Mirum Pharmaceuticals, Inc.
MIRM · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -2.48 | 1.80 | 0.97 | -0.33 |
| FCF Yield | 0.93% | 0.47% | -0.09% | -0.25% |
| EV / EBITDA | 474.19 | 626.22 | -576.95 | -142.15 |
| Quality | ||||
| ROIC | 0.42% | -0.86% | -2.69% | -4.33% |
| Gross Margin | 80.80% | 81.67% | 79.37% | 77.09% |
| Cash Conversion Ratio | 13.66 | -2.05 | 0.13 | 0.21 |
| Growth | ||||
| Revenue 3-Year CAGR | 48.28% | 54.76% | 58.21% | 63.51% |
| Free Cash Flow Growth | 231.49% | 695.10% | 60.65% | 17.90% |
| Safety | ||||
| Net Debt / EBITDA | 4.06 | 21.69 | -26.33 | -6.47 |
| Interest Coverage | 7.33 | -1.39 | -4.22 | -6.77 |
| Efficiency | ||||
| Inventory Turnover | 1.06 | 1.02 | 1.03 | 1.02 |
| Cash Conversion Cycle | 114.27 | 95.55 | 119.46 | 101.63 |